MCTIC
BIIB icon

MacGuire Cheswick & Tuttle Investment Counsel’s Biogen BIIB Stock Holding History

MacGuire Cheswick & Tuttle Investment Counsel’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-741
Closed -$210K – 90
2016
Q4 		$210K Buy
+741
New +$220K 0.04% 86

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MacGuire Cheswick & Tuttle Investment Counsel's BIIB Position: Q1 2017 in Review

MacGuire Cheswick & Tuttle Investment Counsel sold out of Biogen (BIIB) in Q1 2017, closing a stake of 741 shares — an estimated $210K sold.

MacGuire Cheswick & Tuttle Investment Counsel first reported a position in BIIB in Q4 2016 and held it in 1 quarter. The position peaked at $210K in Q4 2016. 1,019 funds tracked by Wall St. Rank hold BIIB as of Q1 2017.

  • MacGuire Cheswick & Tuttle Investment Counsel reported no remaining Biogen position as of Q1 2017 after selling out during the quarter.
  • MacGuire Cheswick & Tuttle Investment Counsel sold 741 Biogen shares in Q1 2017, an estimated $210K.
  • MacGuire Cheswick & Tuttle Investment Counsel first reported a position in Biogen in Q4 2016 and held it in 1 quarter.
  • MacGuire Cheswick & Tuttle Investment Counsel's Biogen position peaked at $210K in Q4 2016.
  • 1,019 funds tracked by Wall St. Rank held Biogen as of Q1 2017.

Based on MacGuire Cheswick & Tuttle Investment Counsel's 13F filing for Q1 2017, filed 28 Apr 2017.